Aspire Biopharma Holdings, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Aspire Biopharma Holdings, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2024
FY2025
Revenue
0.01
Cost of revenue
0.01
Gross profit
-0
Research and development
0.14
0.92
Selling and marketing
0.13
0.79
General and administrative
0.98
1.34
0.94
17.6
Operating expenses
0.98
1.34
1.21
19.4
Operating income
-1.21
-19.4
Interest expense
0.01
0.1
8.53
Interest income
4.32
5.81
0.55
Other non-operating income
4.32
5.8
-0.1
-5.13
Pre-tax income
-1.31
-24.5
Income tax
0
Net income
3.34
4.46
-1.31
-24.5
EPS, diluted
-1.90
-16.38
Shares, basic (weighted)
0.69
1.49
Shares, diluted (weighted)
0.69
1.49
Balance sheet
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.5
0.01
0
1
Inventory
0.25
Other current assets
0.6
0.08
0.14
0.06
Total current assets
1.1
0.08
0.15
1.31
Total assets
300
20
0.15
1.31
Accounts payable
0.18
0.15
0.31
1.01
Accrued liabilities
1.01
Total current liabilities
0.3
0.4
1.69
7.59
Total liabilities
11.1
0.4
1.69
7.69
Paid-in capital
11
1.24
20.9
Retained earnings
-9.94
-11.3
-2.78
-27.3
Shareholders' equity
-9.94
-0.49
-1.54
-6.38
Total equity
-9.94
-0.49
-1.54
-6.38
Total liabilities and equity
300
20
0.15
1.31
Shares outstanding
0.69
0.12
Cash flow statement
FY2022
FY2023
FY2024
FY2025
Net income
3.34
4.46
-1.31
-24.5
Stock-based compensation
0
14.1
Change in inventory
-0.25
Change in payables
0.13
-0.03
0.25
-0.32
Cash from operations
-1.41
-0.65
-0.27
-4.92
Cash from investing
-295
285
13.8
Stock issued
0.26
Share buybacks
-285
-13.8
Cash from financing
297
-285
0.26
5.92
Net change in cash
0.5
-0.5
-0.01
1
Interest paid
0.04
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.32 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
-25.0%
Gross profit / revenue.
Operating margin
-7,495.0%
Operating income / revenue.
Net margin
-11,314.0%
Net income / revenue.
Operating cash flow margin
-7,358.0%
Cash from operations / revenue.
Return on equity (ROE)
-94.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-81.6%
Net income / average total assets.
R&D / revenue
858.2%
Research and development expense / revenue.
Stock-based pay / revenue
175.0%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
786.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-83.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
116.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.99x
Current assets / current liabilities.
Quick ratio
7.22x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.22x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.09
Revenue / diluted weighted shares.
Operating cash flow per share
-$6.92
Cash from operations / diluted weighted shares.
Book value per share
$9.08
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
119x
Market cap / revenue.
P/B
0.99x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.99x
Market cap / tangible book value, when positive.
Earnings yield
-94.7%
Net income / market cap (the inverse of P/E).
What was Aspire Biopharma Holdings, Inc.'s revenue in fiscal 2025?
Aspire Biopharma Holdings, Inc. reported revenue of $6.2K for fiscal 2025.
Was Aspire Biopharma Holdings, Inc. profitable in fiscal 2025?
No. It reported a net loss of $24.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.